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        The infl  ammatory arthritides are an important 
health problem  —  rheumatoid arthritis (RA) af-
fects     1% of the world  ’  s population. Genetic 
factors are known to have a substantial impact 
on the incidence and progression of RA, but 
the low concordance rate of this disease in 
monozygotic twins (    20%) raises the possibil-
ity of environmental factors also exerting a cru-
cial infl  uence (  1  ). Indeed, there have been many 
reports of correlations between viral or bacterial 
infections and the onset of RA in humans (  2  ). 
Furthermore, several animal models of infl  am-
matory arthritis are initiated by one or another 
microbial constituents (  3  ). 
  Cells of the innate immune system detect 
the intrusion of pathogens by recognizing con-
served sequence motifs embedded within mole-
cules expressed by the intruders (  4  ). Some 
examples of such motifs are LPS, peptidogly-
cans (PGNs), double- and single-stranded RNAs, 
and unmethylated DNA CpG motifs (CpGs). 
These   “  pathogen-associated molecules (PAMs)  ”   
are specifi  cally recognized by sets of recep-
tors, the best characterized of which are the 
toll-like receptor (TLR) family members (  4, 5  ). 
PAMs and their receptors provide powerful 
molecular probes for assessing a potential impact 
of microbes on the initiation and progression 
of arthritis. Indeed, administration of PAMs 
promoted disease development in several mouse 
models of arthritis (  6  –  8  ). 
  Given their potential importance, we decided 
to explore the roles of TLRs and their ligands 
in the K/BxN mouse model of infl  ammatory 
arthritis, which is a particularly convenient sys-
tem for performing mechanistic dissection. This 
model has the additional advantage of not re-
quiring adjuvants, which often contain TLR 
  ligands, for disease induction, thereby avoiding 
potential problems of synergy. K/BxN mice ex-
press a transgene-encoded TCR that is   reactive 
to a self-peptide derived from the ubiquitously ex-
pressed enzyme glucose-6-phosphate-isomerase 
(GPI), presented by the MHC class II molecule 
A  g7   (  3  ). Beginning at 3  –  5 wk of age, K/BxN 
mice spontaneously develop an autoimmune/
infl  ammatory disease with many features in com-
mon with those of human RA (  3  ). Conveniently, 
transfer of serum from arthritic mice into healthy 
nontransgenic animals induces arthritis in a highly 
synchronized and reproducible fashion (  3  ). Im-
portantly, this system does not require LPS to 
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  Unmethylated CpG-oligodeoxynucleotides (ODNs) are generally thought of as potent adjuvants 
with considerable therapeutic potential to enhance immune responses against microbes 
and tumors. Surprisingly, certain so-called stimulatory CpG-ODNs strongly inhibited the 
effector phase of infl  ammatory arthritis in the K/BxN serum transfer system, either preven-
tively or therapeutically. Also unexpected was that the inhibitory infl  uence did not depend 
on the adaptive immune system cells mobilized in an immunostimulatory context. Instead, 
they relied on cells of the innate immune system, specifi  cally on cross talk between CD8         
dendritic cells and natural killer cells, resulting in suppression of neutrophil recruitment to 
the joint, orchestrated through interleukin-12 and interferon-    . These fi  ndings highlight 
potential applications of CpG-ODNs and downstream molecules as antiinfl  ammatory agents. 1912 ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
a mechanism that relies solely on cells of the innate immune 
system, without the requirement for cells of the adaptive 
immune system seen with other CpG-mediated immuno-
therapeutic activities. 
    RESULTS   
  Certain CpGs inhibit K/BxN serum-transferred arthritis 
  As a fi  rst approach to exploring the role of TLRs and their 
ligands in the eff  ector phase of infl  ammatory arthritis, we 
screened several TLRs for the ability to infl  uence K/BxN 
  serum-transferred disease. As might have been expected (  7, 8  ), 
LPS exacerbated arthritis development in B6 mice when ad-
ministered i.p. 2 d before K/BxN serum transfer (  Fig. 1 A  ), 
be eff  ective, unlike collagen antibody  –  induced arthritis (  7  ), 
again, simplifying the interpretation of results. Arthritis is a 
very complex, polygenic, and multifactorial disorder, so a 
major attraction of this serum-transfer system is that it allows 
one to focus on the infl  ammatory eff  ector phase of disease, 
without the complicating infl  uences of the autoimmune ini-
tiation phase. 
  To delineate points of potential environmental impact 
specifi  cally in the arthritis eff  ector phase, we examined the 
infl  uence of selected TLRs and TLR ligands in the K/BxN 
serum-transfer system. Results from these experiments con-
fronted us with two surprises: a potent antiinfl  ammatory 
eff  ect exerted by so-called stimulatory TLR9 ligands, and 
  Figure 1.     Some CpGs inhibit K/BxN serum-transferred arthritis. (A) Mean ankle thickening (left) or clinical score (right) of mice injected i.p. with 
50     g LPS, 10 nmol CpG-ODN (ODN1668), or nothing on day   −  2 and with 100     l of K/BxN serum i.p. on day 0. The black and white arrows indicate adminis-
tration of serum and various TLR ligands, respectively. Representative of two independent experiments (  n    3 mice/group). (B) Ankle thickening of mice 
treated with the optimum serum dose (150     l K/BxN serum on day 0 and 2), together with stimulatory ODNs (ODN1668, ODN1826, ODN1758, ODN1643, 
and ODN1585), a suppressive ODN (H154), or nothing on day 0 and 2. Except for ODN1558, all bases of the ODNs used in this paper were phosphorothio-
ate modifi  ed. Effects were evaluated as disease incidence, mean of maximal clinical score, and mean of maximal ankle thickening. CpG dinucleotides are 
underlined. (C) Mean of ankle thickening (left) or clinical score (right) of mice treated with 150     l K/BxN serum on day 0 and 2, either with or without 
ODN1668 on day 4 and 6 (  n    3). The black and white arrows indicate administration of serum and ODN1668, respectively. Representative of two inde-
pendent experiments.     JEM VOL. 204, August 6, 2007 
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not (  Fig. 1 B  ). ODNs 1826 and 1758 also had a suppressive 
eff  ect, although in the latter case it was only a moderate 
one; ODNs 1585, D19 (unpublished data), 1643, and H154 
had no detectable infl  uence. The two CpG-ODNs with the 
strongest infl  uence on disease development are the most sim-
ilar in sequence, diff  ering by only two nucleotides at the 3     
end. Both of these are so-called CpG-B-ODNs, which are 
characterized by having one or more CpG sequences on a 
fully phosphorothioate-modifi   ed backbone, and by being 
particularly stimulatory for B cells (  9  ). The ODNs with no 
eff  ect on arthritis included ones classifi  ed as CpG-B (1643); 
whether assayed as ankle thickening (left) or as a clinical score 
(right).   Preparations of PGNs, Pam3Cys4, and poly I:C had a 
similar eff  ect when tested under the same protocol (unpub-
lished data). In contrast, and surprisingly, injection of the CpG 
oligodeoxynucleotide (ODN) 1668 (  Fig. 1 B  ) severely inhibited 
development of disease (  Fig. 1 A  ). None of the TLR ligands 
was able to induce arthritis when injected alone i.p. (unpublished 
data), in contrast to what has been reported for intraarticular 
  injection of unmethylated CpGs (  6  ), for example. 
  Interestingly, although some CpG-ODNs were capable 
of inhibiting K/BxN serum-transferred arthritis, others were 
  Figure 2.     ODN1668 impacts early in arthritogenesis. (A) HE-stained ankle sections from mice 8 d after K/BxN serum transfer with or without 
ODN1668. Bar, 0.25 mm.   n    2. (B) Serial ankle cryostat sections from B6 mice 8 d after K/BxN serum transfer with or without ODN1668. Stained with 
anti-C3d Ab (i and iv), anti-IgG Ab (ii and v), or anti-GPI Ab (iii and vi). Arrow indicates the interface between the cartilage and articular cavity, where ICs 
can accumulate. Bar, 0.25 mm.   n    2. (C) CAE-stained ankle sections from mice 1 d after K/BxN serum (200     l) transfer with or without ODN1668. Many 
hypersegmented neutrophils with red cytoplasmic staining (white arrow) can be observed in the serum-treated group; in contrast, only resident mast 
cells (black arrow) and normal loose connective tissue can be seen in the serumCpG-treated group. Bar, 25     m. Results on the incidence of neutrophil 
infi  ltration from six mice in each group are tabulated. (D) Mice were treated with PBS (i and ii) or CpG (iii and iv), followed 1 h later with Cy5.5 vascular 
probe. 10 min after probe injection, 200     l of normal (i and iii) or K/BxN (ii and iv) serum was transferred. Confocal micrographs of hindpaws were ob-
tained every 3 s for 5 min before and 10 min after serum injection. (left) Images taken at 10 min after serum injection. The mean maximal leakage rate 
(right) was calculated by using the fi  rst derivative of rate curves generated by plotting the mean fl  uorescence intensity of individual confocal micrographs 
obtained every 3 s after serum injection. Bar, 0.5 mm.   n    5 mice/group. Results are plotted as the mean      the  SEM.   1914 ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
CpG-A, with their mixed phosphorothioate/phosphodiester 
backbone, central CpG-containing palindrome, and terminal 
polyG motifs (1585); and CpG-N, which can neutralize the 
eff  ects of immunostimulatory CpGs, including their induction 
of arthritis in certain contexts (  10  ). The one CpG-N assessed, 
H154, was also unable to suppress the negative eff  ect of CpG-Bs 
on arthritis in our system (unpublished data). 
  ODN1668 was optimally eff  ective at inhibiting K/BxN 
serum-transferred arthritis when introduced coincident with, 
or shortly before injection of, the arthritogenic serum. How-
ever, it also had effi   cacy in a therapeutic mode, when admin-
istered as long as 4 d after serum transfer (  Fig. 1 C  ). It did not 
seem to revert symptoms to the predisease state, but rather to 
stop them in their tracks. 
  CpG-ODNs operate over a time window between 
the opening of the vasculature and the infl  ux of 
infl  ammatory cells 
  Mechanisms of pathogenesis in the K/BxN serum-transfer 
system have been extensively dissected (  3, 8, 11  –  14  ). Quite 
similar to a reverse-passive Arthus reaction, arthritis devel-
opment entails the following, sequentially: GPI  –  anti-GPI 
immune complex (IC) formation; activation of infl  ammatory 
and probably endothelial cells; induction of macromolecular 
leakage in joint vessels; complement activation; infl  ammatory 
cell infl  ux; an amplifi  cation loop resulting in massive cytokine 
production; leukocyte recruitment and synovial hyperplasia; 
and, ultimately, joint destruction. To delineate precisely when 
CpGs impinge on the arthritogenic process, we evaluated 
their eff  ect on the diff  erent disease subphenotypes that had 
been instrumental in constructing this pathogenetic scenario. 
  Consistent with the observed dampening of infl  ammation 
signaled by a reduction in ankle swelling, hematoxylin and 
eosin (HE)  –  stained ankle sections taken from mice 8 d after 
coadministration of K/BxN serum and ODN1668 revealed 
an absence of synovial hyperplasia and leukocyte infi  ltration 
(  Fig. 2 A  ).   IC deposition and complement activation, de-
tected as GPI/IgG/C3d costaining on cryostat sections, was 
also absent from the ankles of serum/CpG-cotreated animals, 
although there was weak GPI binding at the cartilage  –  articu-
lar cavity interface (  Fig. 2 B  ), as expected (  15  ). Neutrophil 
recruitment was assayed 1 d after serum      CpG administra-
tion by staining ankle sections with HE and chromogenic 
chloroacetate esterase substrate (CAE), which specifi  cally iden-
tifi  es granulocytes/neutrophils. At this time point, the disease 
is still at an early stage, so only 3 out of 6 mice injected with 
serum alone showed infi  ltration of neutrophils; in contrast, 
none of the animals coinjected with ODN1668 exhibited 
neutrophil recruitment (  Fig. 2 C  ). 
  However, in serum/CpG-cotreated animals the typical 
vascular permeability to macromolecules that can be visualized 
by laser-scanning confocal microscopy of an immobilized heel 
in vivo in real time, subsequent to injection of a Cy5.5-labeled 
graft copolymer imaging reagent, was present (  Fig. 2 D  , left; 
compare iv and ii). Specifi  cally, the maximum rate of leak was 
the same in K/BxN serum-transferred mice with or without 
  Figure 3.     The molecular elements required for ODN1668-mediated 
protection. (A) Ankle thickening of WT or TLR9-KO mice treated i.p. 
with 10 nmol of ODN1668 and 150     l of K/BxN serum on day 0 and 2 or 
with serum alone. Results are plotted as the mean      the SEM.   n     3 – 4/
group. IL-12 and IFN-     are critical for the CpG-mediated inhibitory effect. 
(B) Mean ankle thickening of IL-12p35     /     and  IFN-      /     mice treated with 
K/BxN serum alone or together with ODN1668. Representative of two inde-
pendent experiments.   n    3 mice/group. The black and white arrows indi-
cate administration of serum and ODN1668, respectively. (C) Various ODNs 
were injected i.p. into B6 mice, and the spleens were collected 4 h later. Fold 
induction of   IFN- g    and   IL-12p40   transcripts in spleens were quantitated by 
semiquantitative RT-PCR as described in the Materials and methods. Results 
were compiled from three independent experiments with four mice per 
group. (D) Serum levels of IL-12 and -23 were measured at the indicated 
time points after ODN1668 injection via ELISA.   n    2 mice/group for each 
time point. IFN-     induction is a driving element. (E and F) B6, IL-12p35     /   , 
or IFN-       /     mice were treated with ODN1668 for 4 h, and fold induction 
of cytokine transcripts in splenocytes was determined as in D, shown as 
IL-12p35     /     versus WT (E) or IFN-       /     versus WT (F). Results were compiled 
from four independent experiments with 6  –  7 mice/group.     
coadministration of ODN1668 (  Fig. 2 D  , right). Injection of 
this CpG in the absence of serum did not provoke vessel leakage 
(  Fig. 2 D  , compare iii and i). Because the vascular permeability JEM VOL. 204, August 6, 2007 
ARTICLE
1915
provoked by serum transfer depends on ICs (  11  ), it would 
appear that ODN1668 did not compromise GPI/anti-GPI IC 
formation per se, which is consistent with the observation of 
indistinguishable anti-GPI antibody (Ab) titers in the blood in 
the presence or absence of this ODN (unpublished data). 
  Thus, the window within which CpGs impinge on the 
unfolding of arthritis in this system is delimited on one side 
by opening of the vasculature (  	  2 min after serum injection) 
and on the other side by infl  ammatory cell infl  ux subsequent 
to IC deposition, and the consequent activation of comple-
ment (  
  24 h after injection). 
  The CpG-mediated inhibitory effect is signaled 
through TLR9 
  CpGs are known to exert their immunostimulatory eff  ects 
through binding to TLR9 (  16  ). Yet, because it has been hy-
pothesized that other receptors might be involved in CpG-
induced activation (  17  ), and because binding of ODNs 1668 
and 1826 to TLR9 has generally been associated with stimu-
latory rather than suppressive infl  uences (  9  ), we wished to 
verify that CpG-mediated inhibition of K/BxN serum-trans-
ferred arthritis actually does result from their signaling through 
TLR9. First,   TLR9  -transfected human embryonic kidney 
(HEK) 293 cells were stimulated with the various ODNs 
whose properties are depicted in   Fig. 1 B  , and induction of a 
  luciferase   reporter gene driven by NF-    B  –  responsive regula-
tory elements was measured. There was a clear correlation 
between the strength of the TLR9-transduced signal and its 
disease-dampening capacity, ODNs 1668 and 1826 being 
strongest according to both criteria, ODN1758 being inter-
mediate, and ODN1643 and H154 being the weakest (Fig. 
S1, left, available at http://www.jem.org/cgi/content/full/
jem.20070285/DC1). None of the CpG-ODNs elicited a 
signal in control   TLR2  -transfected HEK-293 cells (Fig. S1, 
right). Second, according to data on KO mice, TLR9 was 
not required for arthritis to develop in response to K/BxN 
serum transfer; however, it was needed for the ODN1668-
induced inhibition of this process (  Fig. 3 A  ).   
  CpG-mediated inhibition of arthritis requires IL-12 
and IFN-     
  To begin dissecting the molecular mechanisms underlying 
the dampening of K/BxN serum-transferred arthritis by 
ODN1668, we screened disease inhibition in several mouse 
strains defi  cient in the expression of cytokines, particularly 
some of those previously reported to operate downstream of 
TLR9 signaling. These experiments were, of course, limited 
to an assessment of strains that could develop disease in the 
fi  rst place, i.e., not those devoid of IL-1 or TNF-    . 
  Both IL-12p35 and IFN-     (  Fig. 3 B  ) were required for 
ODN1668 to exert its suppressive eff  ect, as transfer of serum 
plus CpG, versus serum alone, into the corresponding KO 
strains provoked arthritis with the same kinetics and severity, 
i.e., with no sign of a CpG-mediated inhibitory eff  ect. In 
contrast, IL-6 was not needed for eff  ective inhibition (un-
published data). 
  There was an excellent correlation between the ability of 
a given ODN to inhibit arthritis and its capacity to induce 
  IFN-       and   IL-12p40   gene expression in spleens of recipient 
mice 4 h after injection (compare   Fig. 1 B and Fig. 3 C  ). In 
contrast, splenocyte transcription of several other cytokine 
genes (e.g.,   TNF-      ,   IL-15  ,   IL-2  , and   IL-1  ) demonstrated no 
such correlation (unpublished data). The increase in   IL-12p40   
expression was associated with a transient augmentation in 
secretion of the IL-12 cytokine, itself, rather than of IL-23, 
which also contains the p40 subunit, as indicated by ELISA 
measurements of serum-cytokine levels (  Fig. 3 D  ). 
    IL-12p40   expression was important for induction of   IFN-       
transcription, although some increase in transcript levels was 
  Figure 4.     Administration of IFN-     prevents arthritis development 
and blocks neutrophil recruitment by binding to their IFN-     receptors. 
(A) Mean ankle thickening of mice treated with 150     l K/BxN serum 
on day 0 and 2, together with daily i.p. injection of 50    g  IFN-    or  vehicle 
control (10% FBS-RPMI) for 7 d. Results were compiled from two inde-
pendent experiments.   n    4 mice/group. (B) Purifi  ed neutrophils from WT 
B6 (i, ii, and iii) or IFN-    R KO (iv) mice were treated with IFN-     (iii and iv) 
or not (i and ii), and were transferred into arthritic B6 mice. Bar, 0.5 mm. 
Results shown are images of neutrophils (green) in the infl  amed ankles. 
(C) The bar graphs depict averages of neutrophil number minus back-
ground (no serum group [B, i]; mean number is 5.3 from 4 mice).   n     4 – 6 
for each group. Error bars represent the SD.     1916 ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
still evident in its absence (  Fig. 3 E  );   IFN-       expression also 
promoted the induction of   IL-12   transcription (  Fig. 3 F  ). As 
discussed below, this mutual dependence might be taken as 
evidence of a feed-forward loop. 
  Strikingly, systemic administration of IFN-     was an eff  ec-
tive inhibitor, by itself, of serum-transferred arthritis, arguing 
that systemic mechanisms are probably in play (  Fig. 4 A  ).   Be-
cause CpG blocked neutrophil accumulation in the joints, 
and IFN-     was identifi  ed as the downstream eff  ector of CpG, 
we next examined whether IFN-     prevented joint infl  amma-
tion by acting directly on neutrophil migration. Using a novel 
laser-scanning, time-lapse, intravital imaging system, we found 
that IFN-     administration did inhibit recruitment of WT 
neutrophils into infl  amed joints; however, this inhibition was 
lost when neutrophils from IFN-    R KO animals were used 
(  Fig. 4, B and C  ). Note that the absence of IFN-    R on neu-
trophils did not, in and of itself, infl  uence their migration 
into the joint under the infl  uence of serum alone (unpub-
lished data). Therefore, IFN-     directly blocks neutrophil 
migration by binding to their IFN-     receptors. Without neu-
trophil migration, arthritis cannot set in. 
  The case for DC  –  NK cell crosstalk 
  The combined requirement for IL-12 and IFN-    , and their 
interdependent expression, evoke recent fi  ndings on the 
  Figure 5.     DCs and NK cells are critical players in CpG-mediated 
inhibition. (A) Mice were treated with PBS, 10 nmol ODN1643, or 10 nmol 
ODN1668 on day 0 and 2. Spleens were harvested on day 8, and cell types 
were identified by their surface markers as follows: T cells 
(CD3   NK1.1      ), NKT cells (CD3   NK1.1   ), NK cells (CD3      NK1.1   ), B cells 
(B220   CD11c      ), plasmacytoid DCs (pDCs; B220   CD11c int ),  conventional 
DCs (cDC; B220      CD11c high  ), macrophages (Mac; Gr1      CD11b  ),  hetero-
geneous myeloid cells (HMCs; Gr1  dull CD11b   ), and neutrophils 
(Gr1  high CD11b   ). A dot plot from one representative mouse out of three is 
shown. The percentage of total live cells (mean      the SD) from 3 mice is 
indicated. Representative of two experiments. (B) Same as in A; absolute 
cell number is shown (mean      the SD). Total splenocyte counts were 
as follows: in PBS-treated mice, 128, 84, and 84 million; in ODN1643-
injected mice, 100, 68, and 96 million; and in ODN1668-injected mice, 
328, 384, and 328 million. All cell types, except for T cells, are statistically 
signifi  cant (P   
   0.05,  Student ’ s   t   test) in both the PBS versus ODN1668 
and ODN1643 versus ODN1668 comparisons. (C) B6 mice were injected 
i.p. with ODN1668 or PBS, and 4 h later, spleens were harvested and 
sorted into various cell types as defi  ned in A; except for DCs, NK cells 
were excluded before sorting into the Mac and HMC populations; the DC 
population includes both the plasmacytoid and conventional subsets. Fold 
induction of   IL-12p40   and   IFN- g   . Transcripts in various cell types were 
measured by RT-PCR as in   Fig. 3 C  . Results shown are the average of fold 
inductions from two independent experiments with a pool of 3 spleens/
group. (D) Mice were injected i.p. with ODN1668, and spleens were har-
vested after 1, 2, or 4 h. NK cells, pDC, CD8       DCs, and CD8       DCs  were 
sorted (Figs. S2 and S9) and examined for their IL-12  p40   and  IFN-    tran-
script induction. Results shown are the average fold inductions from two 
independent experiments. (E) Splenocytes from TLR9     /     CD45.2 and WT 
CD45.1 congenic mice were mixed at a 1:1 ratio and cultured with 
ODN1668 for 2 or 4 h. TLR9     /     and WT DC or NK cells were sorted based 
on their CD45 alleles, and were examined for their IL-12  p40   and  IFN-   
transcript induction. The results shown are the average of fold inductions 
from two independent experiments. Figs. S2 and S9 are available at 
http://www.jem.org/cgi/content/full/jem.20070285/DC1.   JEM VOL. 204, August 6, 2007 
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mouse strain wherein DCs can be killed off   by diphtheria 
toxin (DT) treatment of transgenic animals expressing the 
simian DT receptor (DTR) primarily on DCs, under the dic-
tates of the mouse CD11c promoter (  21  ). These mice were 
found to lack all CD11c     DC populations, which reduced 
their capacity to control microbial infections. Because it was 
reported that the DC compartment began to reemerge 3  –  5 d 
after DT treatment, we needed to modify our protocol as per 
  Fig. 6 A   (i) to enable us to assay arthritis induction and CpG-
mediated inhibition of it during this short time frame.   The 
DC populations were strongly reduced by this protocol, 
whereas other cell-types, e.g., NK, T, and B cells, were not 
(  Fig. 6   A [ii] and not depicted). Loss of DCs during this time 
frame had no detectable eff  ect on arthritis progression; how-
ever, it did strongly compromise the inhibitory eff  ect  of 
ODN1668 (  Fig. 6   A, iii). 
  IL-15  –  defi  cient mice have a strong defi  ciency in NK cells, 
but also have defi  cits in some populations of T lymphocytes, 
particularly memory T and NKT cells (Fig. S4 A, available at 
http://www.jem.org/cgi/content/full/jem.20070285/DC1) 
(  22  ). However, the CpG-induced, arthritis-inhibitory eff  ect 
was independent of all     /  
   T and B cell populations, as was 
evident with mice carrying a mutation of the   TCR       locus 
or in animals lacking B cells caused by the     MT mutation 
(Fig. S5). IL-15 KO mice were fully susceptible to K/BxN 
serum-transferred arthritis, but not to inhibition of disease 
by ODN1668 (  Fig. 6 B  , left). Because it was recently re-
ported that mice lacking IL-15 also have defects in some DC 
populations (although we did not fi  nd a numerical defi  cit; 
Fig. S4) (  23  ), we tried a second strategy for eliminating NK 
cells. The polyclonal Ab anti  –  asialo-GM1 will deplete NK 
cells, though there are some reports that a subset of CD8     
T cells may be removed as well. Again, however, we know 
that T cells are not required for the CpG-induced suppres-
sion of arthritis (Fig. S5, middle). Anti  –  asialo-GM1 treatment 
reduced NK cells to     30% of the normal level, although not 
depleting the T or NKT cell populations (Fig. S4 B), but did 
not aff  ect serum-induced arthritis. Such treatment did, on the 
other hand, compromise the ability of ODN1668 to inhibit 
disease unfolding (  Fig. 6 B  , right). Together, these two sets 
of fi  ndings on NK cell depletion argue that this cell type has 
a critical role in CpG-mediated inhibition of serum-trans-
ferred arthritis. Again, consistent with the proposed scenario 
of DC  –  NK cell cross talk were results on cytokine gene ex-
pression in the DTR and IL-15 KO mice; a strong reduction 
in both   IL-12   and   IFN-       expression in the former case, with 
residual levels probably being attributable to incomplete DC 
depletion (  Fig. 6 C  , left), but a drop in only   IFN-       transcripts 
in the latter case (  Fig. 6 C  , right). 
    DISCUSSION   
  The therapeutic potential of CpGs has excited great interest of 
late (  24  ). Their potent adjuvant activity can be applied to elic-
iting more eff  ective immune responses to infectious agents or 
tumors. Their ability to bias responses in a T  H  1 direction can 
be harnessed to redirect pathogenic T  H  2 responses, e.g., in the 
importance of the interplay between dendritic and NK cells, 
and the molecular crosstalk between them, in initiating re-
sponses by the innate immune system (  18, 19  ). On one hand, 
DCs can prime, further the activation of, augment the expan-
sion of, and enhance the activities of NK cells through the 
production of cytokines like IL-2, -12, -15, IFN-    /  
  , and 
TNF-    . On the other hand, mostly through the intermedi-
ary of IFN-    , NK cells can enhance the diff  erentiation, sur-
vival, and function of DCs, especially their expression of 
costimulatory molecules and production of IL-12 and TNF-    . 
Because most of the studies responsible for these conclusions 
were performed with cultured cells, the in vivo signifi  cance 
remains somewhat controversial. Nevertheless, we hypothe-
sized that such a scenario underlies the CpG-mediated in-
hibition of K/BxN serum-transferred arthritis, and set out to 
test this notion. 
  As a fi  rst step, we performed a cytofl  uorimetric compari-
son of splenocytes from mice injected with PBS, the control 
CpG 1643, or the arthritis-inhibitory CpG 1668. As detailed 
in   Fig. 5 (A and B)  , most of the examined cell populations 
had increased in number by 8 d after ODN1668 injection, a 
time point when the expansion of spleen cells was maximal 
and the inhibitory eff  ect on arthritis was clearly evident.   In 
particular, there was a striking overrepresentation of NK cells 
(CD3       NK1.1    ; top) augmenting 18-fold in number and ris-
ing fractionally from an average of 4.4  –  22%. 
  Next, we examined cytokine mRNA induction in the 
diff  erent splenocyte populations (  Fig. 5 C  ). The dominant 
IL-12  –  producing cells 4 h after injection of ODN1668 were 
DCs; NK cells were the major producers of IFN-    , although 
NKT and DCs also made low amounts. 
  In mice, splenic CD8         and CD8            DCs both express 
TLR9, and both can be induced to secrete IL-12 after stimu-
lation in culture with CpG (  20  ). However, we found that in 
vivo, CD8        , but not CD8           , DCs were the major cell type 
responsible for CpG-induced IL-12 induction (  Fig. 5 D   and 
Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20070285/DC1). Maximum expression of IL-12 occurred 
at 1 h after CpG injection; in contrast, induction of IFN-     
expression by NK cells maxed later at 4 h. 
  We next sought to determine where TLR9 needed to be 
expressed for DCs to turn up IL-12 expression and NK cells 
to up-regulate IFN-    transcription. CD45.2 TLR9      /      spleno-
cytes were mixed 1:1 with splenocytes from WT CD45.1 
congenic B6 mice, and the mixture was stimulated with 
CpG. TLR9      /      DCs were not induced to express IL-12 (  Fig. 
5 E  , left); a similar result was obtained by staining for intra-
cellular IL-12 (Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20070285/DC1). There was no diff  er-
ence in IFN-     induction in TLR9      /      versus WT NK cells 
(  Fig. 5 E  , right). Thus, CpG engagement on CD8        DCs 
  appears to be the gateway for this antiinfl  ammatory eff  ect, 
inducing IL-12 by the DCs and subsequent activation of 
NK cells to make IFN-    . 
  Lastly, the requirement for DCs and NK cells was assessed. 
Punctual depletion of DCs was performed by exploiting a 1918 ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
activities of CpG-B-ODNs began with TLR9-signaled 
activation of B and DCs and ended with a potent response 
by the adaptive immune system, entailing Abs, T  H  1 cells, and 
cytotoxic CD8  +   T cells (  Fig. 7 A  ) (  9  ).   More recently, this 
scenario was enriched to include DC-induced stimulation 
of NK cells, but it still culminated in and highlighted the 
promotion of more eff  ective T cell and Ab responses (  24, 26  ). 
Cases of CpG-ODNs dampening immune responses have been 
described in the past  —  autoimmune (  27  –  29  ), asthmatic (  30  ), 
or standard T cell (  31  )  —  in nature, but, in all of these studies, 
data, or sometimes just mere   assumption, focused attention on 
context of allergy or asthma. Given this backdrop, the obser-
vation that other PAMs are known to have an enhancing 
  eff  ect on diverse rodent models of infl  ammatory arthritis (  7, 8  ), 
and the precedent that CpGs, themselves, have been reported 
to promote arthritis in more than one model (  6, 25  ), we were 
surprised to fi  nd that ODN1668 could block arthritis devel-
opment in the K/BxN serum-transfer system. Even more 
striking, ODN1668 is one of the few agents thus far found 
to be capable of reversing ongoing arthritis in this system. 
  Our mechanistic studies aff  orded a second surprise. The orig-
inal scenario constructed to account for the immunostimulatory 
        Figure 6.     DCs and NK cells are required for CpG-mediated protection. (A) DCs needed. (top left) Protocol for DC depletion and serumODN1668 
treatment. DTR mice and littermate controls (Tg [  −  ]) were injected with serum on day 0 and 2, followed by DT treatment on day 4; animals were treated 
with ODN1668 or PBS on day 5. (bottom left) Flow cytometric analysis was performed on the splenic DC populations (CD11c    ) of DTR mice after 20-h 
treatment with DT. Tg (  −  ) littermates treated with DT and DTR mice treated with PBS served as negative controls. (right) DC-defi  cient (DTR) mice treated 
with serumPBS or serumCpG, or Tg (  −  ) control littermates were monitored for arthritis progression. Average     ankle thickening subsequent to day 0 
(the commencement of CpG or PBS treatment) is plotted. DT-treated DTR mice with serumPBS,   n    8; DT-treated DTR mice with serumCpG,   n    8; 
DT-treated Tg (-) mice with serumPBS,   n    11; DT-treated Tg (-) mice with serum+CpG,   n    11. (B) NK cells needed. Mean ankle thickening of NK cell  –
 defi  cient (IL-15      /     ) or WT mice after administration of K/BxN serum alone or with ODN1668 in addition. Results compiled from three independent 
experiments with 8  –  9 mice/group. In a similar set-up, NK cell  –  defi  cient mice were generated by injection of anti  –  asialo-GM1 Ab (anti-GM1). Mean ankle 
thickening of NK cell  –  defi  cient (anti-GM1) or control (normal Ig) mice after treatment with K/BxN serum alone on day 0 and 2 or with ODN1668 on day 0 
in addition.   n   = 4 mice/group. (C) Cytokine consequences. IL-15      /      and B6 mice, or DT-treated DTR animals, and their littermate controls were treated 
with ODN1668 for 4 h. (For both DTR and control mice, ODN1668 was injected 20 h after DT treatment.) Fold induction of cytokine transcripts in spleno-
cytes shown as IL-15      /      verse WT, or DTR versus WT, respectively.       JEM VOL. 204, August 6, 2007 
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contexts (  34, 35  ). Another issue is that the various experi-
ments did not always use the same CpG-ODN; sometimes 
CpG-A versus -B, sometimes a diff  erent one of the many 
available CpG-Bs. This element is a critical one, as we saw 
from   Fig. 1 B   that even CpGs of the same class can have very 
diff  erent eff  ects in vivo. Third, the picture that emerges is 
complicated by the diffi   culty for any study to be comprehen-
sive in light of a constantly increasing cast of players. In this 
respect, we have briefl  y explored the roles in CpG-mediated 
protection of several elements that have elicited interest of 
late, including the following: indoleamine 2,3-dioxygenase 
(IDO) (  31  ), interferon-producing killer DCs (IKDCs) (  36  ), 
and plasmacytoid DCs (pDCs). Under a dose of 1-methyl-
tryptophan, which is an IDO inhibitor previously reported to 
reverse the immunoresistance of IDO-expressing tumors (  37  ), 
we did not see any eff  ect on CpG-mediated arthritis inhi-
bition (Fig. S7). This result is consistent with the observa-
tion that the immunosuppressive eff  ect of IDO is known to 
work through T cells (  31, 38  ), whereas CpG-mediated pro-
tection from arthritis is T cell  –  independent (Fig. S5). Like-
wise, the recently identifi  ed IKDC population may not have 
a substantial role in our system, as the majority of NK1.1-
positive cells expanded after CpG treatment were CD11c-
negative (Fig. S8). In contrast, we found that pDCs did have 
a partial eff  ect on CpG-mediated protection from arthritis 
(Fig. S9). Ostensibly, this eff  ect does not operate through the 
NK  –  DC/IL-12  –  IFN-     axis we have focused on in this study, 
as pDCs do not produce either of these two cytokines (  Fig. 
5 D  ). The role of pDC is instead through a secondary axis 
involving Type I IFN (unpublished data). Lastly, existing 
the response of the adaptive immune system (  Fig. 7 B  ). In 
contrast, the arthritis-inhibitory property of ODN1668 de-
scribed in this study did not depend on either B or T cells, and 
thereby refl  ected an infl  uence solely on the operation of the 
innate immune system (  Fig. 7 C  ). The key turned out to be 
cross talk between CD8        DCs and NK cells, which relied 
critically and interdependently on IL-12 produced by the 
former and IFN-     made (mostly) by the latter. The eventual 
outcome of this   “  conversation  ”   was suppression of the recruit-
ment of neutrophils, a direct eff  ect of IFN-     on that cell type. 
At fi  rst glance, our data may also appear reminiscent of the 
recent observations of Katakura et al. on experimental colitis 
(  32  ). However, these authors described only a protective 
eff  ect; in fact, when administered therapeutically, ODN1668 
exacerbated colitis (  33  ). Moreover, in this case, IFN-     was 
pro- rather than antiinfl  ammatory (  33  ). 
  If one considers the extensive body of existing informa-
tion on events downstream of CpG-ODN engagement of 
TLR9 on immune cells, one is faced with a complex, often-
confl  icting set of data (  18, 19  ). An example is the diff  erential 
reliance on priming and facilitating cytokines, such as IL-2, 
IL-15, IFN-    /  
  , and TNF-    , to optimally activate NK cells. 
Part of the diffi   culty in assessing and comparing results is that 
many of them emanate from in vitro experiments on cells 
  derived from various tissues according to diverse expansion 
protocols. For example, this factor could easily explain why 
we saw no infl  uence of IL-2 in either gain-of-function or 
loss-of-function in vivo experiments (Fig. S6, available at 
http://www.jem.org/cgi/content/full/jem.20070285/DC1), 
although it appeared to have a critical role in certain in vitro 
Figure 7.  A comparison of proposed immunotherapeutic mechanisms of CpG. (A) The now classical CpG-mediated therapeutic mechanism in-
volved activation of adaptive immunity, such as enhancement of Th1, CTL, and Ab response. This mechanism has been shown to play a key role in disease 
protection in infection and tumor contexts (24). (B) More recent studies revealed an immunosuppressive effect of CpG. CpG-mediated suppression of an 
undesired immune response was achieved by regulating acquired immunity in certain allergic reactions or autoimmune diseases. Some examples are 
switching of a Th2 to a Th1 response (30), activating T regulatory T cells (31), and inducing Ig isotype switching (53). (C) The CpG-mediated therapeutic 
mechanism proposed here is an antiinfl  ammatory response that relies solely on cells of the innate immune system. ODN1668 signals through TLR9 on 
CD8DCs to induce IL-12 secretion; IL-12 promotes expression of IFN- by NK cells. The process is amplifi  ed through a feed-forward loop entailing 
DC-produced IL-12 and NK cell–produced IFN-; the resulting elevated systemic levels of IFN- inhibit arthritis development by preventing neutrophil 
recruitment into the joint.1920 ANTIINFLAMMATORY EFFECTS OF TLR LIGANDS | Wu et al.
    MATERIALS AND METHODS   
  Mice.     C57BL/6 (B6), B6.SJL (CD45.1     congenic B6 mice), and NOD/Lt 
(NOD) mice were purchased from The Jackson Laboratory. KRN TCR-
transgenic mice, which were described elsewhere (  50  ), were maintained on the 
B6 genetic background (K/B6). Crossing K/B6 animals with NOD mice gen-
erated arthritic K/BxN off  spring. H-2  g7   congenic mice on the B6 background 
(B6g7) were bred in our animal facility. The various gene-defi  cient mice are 
described in the Supplemental materials and methods (available at http://www
 .jem.org/cgi/content/full/jem.20070285/DC1). All mouse procedures were 
conducted in compliance with federal and institutional guidelines. 
  Reagents.     Reagents are described in the Supplemental materials and methods. 
  Serum-transfer system and evaluation of arthritis.     Optimal serum-
transferred arthritis was induced by i.p. injection of 100  –  150     l of pooled 
serum from 8-wk-old K/BxN mice on days 0 and 2, unless otherwise men-
tioned. Suboptimal arthritis was induced by i.p. injection of 100     l K/BxN 
serum on day 0. Ankle thickness was measured with a caliper (J15 Blet 
micrometer). Each limb was scored on a scale from 0 (no observable swelling) 
to 3 (severe infl  ammation), and the four-limb scores were summed to yield 
a clinical index (maximum 12 points). 
      Histology.     Ankle sections were stained with hematoxylin and eosin or with 
CAE plus hematoxylin as a counterstain, as previously described (  50, 51  ). 
Neutrophils exhibited a red cytoplasmic staining with CAE, which is a 
marker of the myeloid and mast cell lineages that does not stain monocytes, 
macrophages, or basophils. Immunohistology methods are detailed in the 
Supplemental materials and methods, with procedures carried out basically as 
previously described (  15  ). 
  Intravital confocal microscopy.     Microscopy was performed as recently 
published (  11  ), and is detailed in the Supplemental materials and methods. 
  Neutrophil imaging: a laser-scanning, time-lapse intravital micros-
copy system.     The imaging system for neutrophils is described in detail in 
the Supplemental materials and methods. 
  ELISAs.     Anti-GPI Ab titers were measured as previously described (  52  ). 
In brief, recombinant mouse GPI was coated on ELISA plates at 5 mg/ml, 
and diluted mouse sera was added. Subsequently, alkaline phosphatase (AP)  –
  conjugated anti  –  mouse total IgG, followed by AP-conjugated streptavidin, was 
applied. After substrate addition, titers were quantitated according to the 
  optimal density (OD) values from an ELISA reader. Serum levels of IL-12 
and -23 were measured by an ELISA kit, using the instructions provided by 
the company (eBioscience). Capture-Ab clones C18.2 (anti  –  IL-12p35) and 
G23-8 (anti  –  IL-23p19) were specifi  c for their respective cytokines. Both 
detection systems used clone C17.8 as the detection Ab for the p40 subunit 
shared by the two cytokines. Standard curves were generated using the 
recombinant IL-12 or -23 provided by the kit. 
  Flow cytometry.     Abs and fl  ow cytometry techniques are described in the 
Supplemental materials and methods. 
  Cell culture.     An equal ratio of splenocytes from TLR9      /      (CD45.2    ) and 
B6.SJL mice (CD45.1    ) mice were cultured at 2      10  6  /well in 96-well plates 
with 1     M CpG. Cells were harvested after 2 or 4 h and sorted into WT or 
TLR9      /      DC and NK cell populations based on the CD45 alleles expressed. 
  NK cell depletion.     Polyclonal rabbit anti  –  asialo-GM1 Ab (Cedarlane Lab-
oratories) was used for in vivo depletion of NK cells. Mice were injected i.p. 
with 50   μ  l of Ab on days 1, 2, 5, and 9 via serum injection or with an equiva-
lent amount of rabbit gamma-globulin (The Jackson Laboratory). 
  RT-PCR.     RNA was isolated from splenocytes via Trizol and reverse-
transcribed using oligo dT priming and Superscript polymerase (Invitrogen). 
information comes from a mix of mouse and human studies and, 
although the general outline is very similar in the two cases, 
details of the scenario certainly diverge, refl  ecting species dif-
ferences such as the precise cell types that express TLR9 (  9  ). 
  One of the key elements in the CpG-mediated inhibitory 
eff  ect was IL-12. This dependence may explain the divergent 
results with the other TLR ligands we tested, as CpG is a 
much stronger IL-12 inducer than LPS or polyI:C (unpub-
lished data) (  39, 40  ). IFN-     is the other important molecule 
mediating the protective eff  ect. Systemic administration of 
IFN-     prevented arthritis, and this eff  ect appeared to be via 
blockade of neutrophil recruitment to the joint. Neutrophils 
were the direct targets of the IFN-      –  mediated inhibitory ef-
fect, as migration of those devoid of IFN-    R was not inhib-
ited. One attractive hypothesis for IFN-      ’  s downstream 
mode of action is through down-regulation of CXCR4, as 
this cytokine has been described to control neutrophil migra-
tion in diff  erent contexts by posttranslational down-regulation 
of this chemokine receptor (  41, 42  ). 
  Why did CpG-ODNs dampen arthritis in the K/BxN 
serum-transfer system, whereas they promoted disease in other 
arthritis models (  6, 25  )? One explanation is that local CpG 
injection (  6  ) may be proinfl  ammatory, but systemic delivery 
antiinfl  ammatory. Such behavior would parallel observations 
on the eff  ect of administering IFN-     in the collagen-induced 
arthritis model; injection into the paw promoted disease, al-
though back delivery was inhibitory (  43, 44  ). An explanation in 
another case (  25  ) is that the infl  uence of CpGs may diff  er ac-
cording to when they are introduced, with the lymphocyte-
mediated initiation phase being more prone to an enhancing 
eff  ect. One strength of the K/BxN serum-transfer system is 
that it focuses uniquely on the eff  ector phase mediated by 
cells of the innate immune system, which is the phase when 
most patients would present. Lastly, it may be relevant that 
the K/BxN system does not entail other potentially synergistic 
TLR ligands, such as adjuvant (  25  ) or LPS (  7  ). 
  We hope that our fi  ndings will be translatable to the 
human arthritis context. Diff  erences in TLR9 expression 
(or other factors) between mice and humans may mean that 
translation will not be entirely linear, but there should be 
many commonalities in the molecules, cells, pathways, and 
networks involved, so that their identifi  cation and charac-
terization should provide points of access to the inhibitory 
process beyond CpG-ODNs themselves. In this regard, it is 
encouraging that the antiinfl  ammatory properties of IFN-     
are being increasingly appreciated and studied in both spe-
cies, leading to the recognition that some of the critical 
molecular mechanisms are shared, at least as far as can be 
concluded from cell culture experiments (  45  ). Also promis-
ing is that clinical trials of rhIFN-     in small cohorts of RA 
patients in the 1980s and 1990s proved it safe, and usually 
(  46  –  48  ), but not always (  49  ), somewhat eff  ective. It may be 
worth revisiting this strategy, or allied therapeutic strate-
gies, especially if it becomes possible to phenotypically or 
genetically stratify the patients most likely to have a benefi  -
cial response. JEM VOL. 204, August 6, 2007 
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Quantitative RT-PCR was performed on an Mx3000p instrument (Strata-
gene), using gene-specifi  c fl  uorogenic assays (TaqMan; Applied Biosystems). 
Primers and probes are listed in the Supplemental materials and methods. 
The cytokine transcripts in spleens were quantitated by RT-PCR using hypo-
xanthine guanine phosphoribosyl transferase mRNA as an internal standard. 
Fold induction represents relative expression levels of cytokine transcripts 
from CpG-ODN  –  treated mice standardized against the level of cytokine 
transcripts from untreated B6 mice. 
  Online supplemental material.     Fig. S1 shows various signal strengths 
induced by diff  erent CpG-ODNs. Fig. S2 is a FACS plot of both CD8    -
positive and -negative DC population. Fig. S3 shows IL-12 staining in both 
WT and TLR9 KO DC after ODN1668 stimulation. Fig. S4 shows lack 
of NK cells in IL-15 KO mice and depletion of NK cells in anti  –  asialo-
GM1-treated mice. Fig. S5 shows that T and B cells are not required for 
CpG-mediated protection. Fig. S6 demonstrates that IL-2 is not induced 
by CpG stimulation. Fig. S7 shows CpG-mediated protection is IDO in-
dependent. Fig. S8 shows that CpG only induces minor IKDC expansion. 
Fig. S9 shows that pDC is partially required for CpG-mediated protection. 
The online version of this article is available at http://www.jem.org/cgi/
content/full/jem.20070285/DC1. 
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